Adynxx Inc logo

ADYX - Adynxx Inc Share Price

$0.28 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Micro Cap
Market Cap £1.25m
Enterprise Value £7.70m
Revenue £353k
Position in Universe 6087th / 6401
Bullish
Bearish
Unlock ADYX Revenue
Momentum
Relative Strength (%)
1m -47.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -89.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
1.80 4.79 12.2 16.3 2.02 2.22 26.5 31.5 +4.3%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2019, Adynxx Inc revenues decreased from $1.8M to $0K. Net loss before extraordinary items increased 58% to $9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$7.57 to -$1.97.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ADYX Revenue Unlock ADYX Revenue

Net Income

ADYX Net Income Unlock ADYX Revenue

Normalised EPS

ADYX Normalised EPS Unlock ADYX Revenue

PE Ratio Range

ADYX PE Ratio Range Unlock ADYX Revenue

Dividend Yield Range

ADYX Dividend Yield Range Unlock ADYX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ADYX EPS Forecasts Unlock ADYX Revenue
Profile Summary

Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated April 15, 2014
Public Since May 25, 2016
No. of Shareholders: 5,005,211
No. of Employees: 6
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OTC Markets Group
Shares in Issue 5,807,877
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADYX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADYX
Upcoming Events for ADYX
Frequently Asked Questions for Adynxx Inc
What is the Adynxx Inc share price?

As of 12/08/20, shares in Adynxx Inc are trading at $0.28, giving the company a market capitalisation of £1.25m. This share price information is delayed by 15 minutes.

How has the Adynxx Inc share price performed this year?

Shares in Adynxx Inc are currently trading at $0.28 and the price has moved by -89.43% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Adynxx Inc price has moved by -90.61% over the past year.

What are the analyst and broker recommendations for Adynxx Inc?

Of the analysts with advisory recommendations for Adynxx Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Adynxx Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Adynxx Inc next release its financial results?

Adynxx Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-09-30
What is the Adynxx Inc dividend yield?

Adynxx Inc does not currently pay a dividend.

Does Adynxx Inc pay a dividend?

Adynxx Inc does not currently pay a dividend.

When does Adynxx Inc next pay dividends?

Adynxx Inc does not currently pay a dividend.

How do I buy Adynxx Inc shares?

To buy shares in Adynxx Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Adynxx Inc?

Shares in Adynxx Inc are currently trading at $0.28, giving the company a market capitalisation of £1.25m.

Where are Adynxx Inc shares listed? Where are Adynxx Inc shares listed?

Here are the trading details for Adynxx Inc:

Country of listing: United States
Exchange: OTC
Ticker Symbol: ADYX
What kind of share is Adynxx Inc?

Based on an overall assessment of its quality, value and momentum, Adynxx Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Adynxx Inc share price forecast 2020?

Shares in Adynxx Inc are currently priced at $0.28. At that level they are trading at 0.9% discount to the analyst consensus target price of 0.00.

Analysts covering Adynxx Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.17 for the next financial year.

How can I tell whether the Adynxx Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adynxx Inc. Over the past six months, the relative strength of its shares against the market has been -77.61%. At the current price of $0.28, shares in Adynxx Inc are trading at -74.28% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Adynxx Inc PE Ratio?

We were not able to find PE ratio data for Adynxx Inc.

Who are the key directors of Adynxx Inc?

Adynxx Inc's management team is headed by:

Donald Manning - OTH
Julien Mamet - CSO
Rick Orr - CEO
Dennis Podlesak - CHM
Eckard Weber - DRC
Stan Abel - DRC
Matthew Ruth - DRC
Gregory Flesher - DRC
Who are the major shareholders of Adynxx Inc?

Here are the top five shareholders of Adynxx Inc based on the size of their shareholding:

Domain Associates, L.L.C. Venture Capital
Percentage owned: 52.66% (3.06m shares)
TPG Capital, L.P. Private Equity
Percentage owned: 19.15% (1.11m shares)
Mamet (Julien Ph.D.) Individual Investor
Percentage owned: 4.14% (240k shares)
Orr (Rick) Individual Investor
Percentage owned: 2.45% (142k shares)
Celgene Corporation Corporation
Percentage owned: 2.31% (134k shares)
Similar to ADYX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.